New Releases from NCBI BookshelfPortuguese colonial cities : local dynamics, global flows (c.1500-1900) [Internet].Portuguese colonial cities : local dynamics, global flows (c.1500-1900) [Internet].
Post Content
November 20, 2025
Uncategorized
New Releases from NCBI BookshelfClinical and cost-effectiveness of a standardised diagnostic assessment for children and adolescents with emotional difficulties: the STADIA multi-centre RCT.Clinical and cost-effectiveness of a standardised diagnostic assessment for children and adolescents with emotional difficulties: the STADIA multi-centre RCT.
Emotional disorders are common in children and young people and can significantly impair their quality of life. Evidence-based treatments require
Uncategorized
New Releases from NCBI BookshelfExploring Military Exposures and Mental, Behavioral, and Neurologic Health Outcomes Among Post-9/11 Veterans.Exploring Military Exposures and Mental, Behavioral, and Neurologic Health Outcomes Among Post-9/11 Veterans.
Military personnel, who are often exposed to a variety of hazards while deployed, have expressed concerns that mental, behavioral, and
Uncategorized
New Releases from NCBI BookshelfRural Disease Knowledge Anthropological and Historical Perspectives [Internet].Rural Disease Knowledge Anthropological and Historical Perspectives [Internet].
Rural Disease Knowledge examines the ways in which knowledge of rural spaces and environments, on the one hand, and infectious
Uncategorized
New Releases from NCBI BookshelfUnderstanding the Regulatory Landscape to Prevent Opioid-Related Harm in the United States [Internet].Understanding the Regulatory Landscape to Prevent Opioid-Related Harm in the United States [Internet].
In response to the opioid overdose crisis, certain laws, policies, regulations, and guidelines have been passed or issued at the
Uncategorized
New Releases from NCBI BookshelfAtezolizumab (NSCLC, adjuvant): Benefit assessment according to §35a SGB V (expiry of the decision): IQWiG Reports – Commission No. A24-102 [Internet].Atezolizumab (NSCLC, adjuvant): Benefit assessment according to §35a SGB V (expiry of the decision): IQWiG Reports – Commission No. A24-102 [Internet].
Post Content
